Research

Mixed

Tirzepatide treatment for obesity is associated with a very low incidence of macronutrient malnutrition and vitamin deficiency adverse events, with fewer than 1% of patients discontinuing treatment due to nutritional status concerns.

If you are taking tirzepatide for obesity, the risk of developing serious nutritional deficiencies or malnutrition is very low, especially if you follow the recommended dietary counseling. The study showed that fewer than 1% of patients had adverse events related to malnutrition. To stay healthy, focus on the recommended diet (high protein, balanced macros) and attend your lifestyle counseling sessions.

GoodSupportsHIGH confidence
TEAEs potentially related to macronutrient malnutrition were uncommon, as were treatment discontinuations potentially related to nutritional status. Reports of clinically significant vitamin deficiency TEAEs were uncommon... Overall, 0.38 % and 0.06 % of tirzepatide- and placebo-treated participants reached BMI <18.5 kg/m2.
Jaime P. Almandoz et al. · Obesity Pillars · 2026

Why this rating

Based on large randomized controlled trials (N=4726) with placebo controls, though limited by lack of systematic micronutrient biomarker testing.

Source

Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials

Jaime P. Almandoz et al. · Obesity Pillars · 2026

DOI 10.1016/j.obpill.2026.100248

rct · n=4726Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →